ClinicalTrials.gg
CompletedNCT02554981EMPOWERUpdated Jun 1, 2017Results posted

Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®

A Phase 4 interventional study of Cyclosporine 0.05% Ophthalmic Emulsion in Dry Eye Syndromes, sponsored by Allergan. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-06-01.

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies testing cyclosporine in Dry Eye Syndromes — 5 open to participants now, 5 under way, none of them phase 3. Cyclosporine · Dry Eye Syndromes.

Enrollment
21st of 41
51 · median 51
Started
2015
with 2 others
Phase 4
23 of 45
3 open now
Registered
18th of 45
by date
Lead sponsor
4 of 45
Allergan

Among the 45 studies testing cyclosporine in Dry Eye Syndromes, this one is the 21st largest by enrollment of the 41 interventional ones that give a count, is one of 3 that started in 2015, is one of 23 in phase 4, and was the 18th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

5 of the 45 studies testing cyclosporine in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About cyclosporine

Cyclosporine: first FDA approval 1983 (SANDIMMUNE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing cyclosporine in Dry Eye Syndromes, or all of them as a file.
02

Study summary

This study will evaluate the efficacy of Restasis® in participants with dry eye disease who engage in electronic visual tasking.

03

Conditions studied

  • Dry Eye Syndromes

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has Eye Symptoms when using video display terminals
  • Has a reported history of dry eye in both eyes.

Exclusion criteria

Exclusion:

  • Diagnosed with eye infection or active inflammation.
  • Has worn contact lenses within the past 7 days or anticipated use during the study.
  • Has used any eye drops within 2 hours.
  • Has had laser-assisted in situ keratomileusis (LASIK) within 12 months.
  • Has used Restasis® within 90 days.
  • Has had any eye and or/lid surgeries within 6 months.
  • Has had cataract surgery in either eye.
  • Has current punctal occlusion or anticipate a change in punctal occlusion status at any point during the study.
  • Is currently taking any topical ophthalmic prescriptions or over-the-counter solutions, artificial tears, gels or lid scrubs that cannot be discontinued for the trial duration.
  • Use of medication known to cause ocular drying that is not on a stable dose for at least 30 days.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    RESTASIS®

    1 drop of RESTASIS® ophthalmic emulsion instilled in each eye twice a day for 6 months.

    Drug: Cyclosporine 0.05% Ophthalmic Emulsion

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Total Corneal Staining Score With Fluorescein in the Worse Eye

    Total corneal staining with fluorescein was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).

    Time frame: Baseline, Month 6

  2. Change From Baseline in the Total Conjunctival Staining Score With Fluorescein in the Worse Eye

    Total conjunctival staining with fluorescein was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The sum of the total includes 2 regions of the conjunctiva, resulting in a maximum possible score of 8 (severe staining score of 4 in both regions). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).

    Time frame: Baseline, Month 6

  3. Change From Baseline in the Central Region Staining Score With Fluorescein in the Worse Eye

    Staining with fluorescein in the central region of the eye was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).

    Time frame: Baseline, Month 6

  4. Change From Baseline in the Total Corneal Staining Score With Lissamine Green in the Worse Eye

    Total corneal staining with lissamine green was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).

    Time frame: Baseline, Month 6

  5. Change From Baseline in the Total Conjunctival Staining Score With Lissamine Green in the Worse Eye

    Total conjunctival staining with lissamine green was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The sum of the total includes 2 regions of the conjunctiva, resulting in a maximum possible score of 8 (severe staining score of 4 in both regions). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).

    Time frame: Baseline, Month 6

  6. Change From Baseline in the Central Region Staining Score With Lissamine Green in the Worse Eye

    Staining with lissamine green in the central region of the eye was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).

    Time frame: Baseline, Month 6

  7. Change From Baseline in Font Size

    The minimum font (letter) size read correctly was assessed. Smaller font size (less points) indicates better ability. A negative change from Baseline indicates an improvement and a positive change from Baseline indicates a worsening.

    Time frame: Baseline, Month 6

  8. Change From Baseline in Words Read Incorrectly

    The numbers of words read incorrectly are counted. A positive change from Baseline indicates a worsening (more words read incorrectly) and a negative change from Baseline indicates an improvement.

    Time frame: Baseline, Month 6

  9. Change From Baseline in Time to Read Passage

    The time to read passage (selected portion of text ) in seconds was assessed. A negative change from Baseline indicates an improvement (less time to read the passage).

    Time frame: Baseline, Month 6

  10. Change From Baseline in Reading Rate

    Reading speed was assessed as the number of words read correctly calculated as words/minute. A positive change from Baseline indicates an improvement (more words read correctly/minute) and a negative change from Baseline indicates a worsening (less words read correctly/minute).

    Time frame: Baseline, Month 6

Secondary outcomes

  1. Change From Baseline in Tear Film Break Up Time (TFBUT) in the Worse Eye

    TFBUT is defined as the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. The worse eye is defined as the Worse Eye at Baseline. A positive number change from Baseline indicates improvement and a negative number change from Baseline indicates a worsening.

    Time frame: Baseline, Month 6

  2. Change From Baseline in Ocular Protection Index (OPI) 2.0 in the Worse Eye

    A device was used to assess OPI 2.0. This technology measures blink and tear film break-up area. These values demonstrate the average area of tear deficiency/corneal exposure. The worse eye is defined as the worse eye at Baseline. A negative value indicates an improvement in corneal protection.

    Time frame: Baseline, Month 6

  3. Change From Baseline in Interblink Interval (IBI) in the Worst Eye

    A device was used to assess IBI. The IBI measures the time in seconds between blinks in the worse eye. A positive number change from baseline indicates a worsening (more frequent blinks) and a negative number change from baseline (less frequent blinks) indicates an improvement.

    Time frame: Baseline, Month 6

  4. Change From Baseline in OSDI© Total Score

    The OSDI© questionnaire consists of 12 questions measuring the presence of ocular symptoms. Each of the 12 questions was assessed using a 5-point scale (where 0=none of the time and 4=all of the time). The score is converted to a 0 to 100 point score where 0 is no symptoms and 100 is most symptoms. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Month 6

  5. Change From Baseline in Driving at Night on the OSDI©

    The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Driving at Night question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening.

    Time frame: Baseline, Month 6

  6. Change From Baseline in Working With a Computer or Bank Machine on the OSDI©

    The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Working with a Computer or Bank Machine question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening.

    Time frame: Baseline, Month 6

  7. Change From Baseline in Watching Television (TV) on the OSDI©

    The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Watching TV question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening.

    Time frame: Baseline, Month 6

  8. Change From Baseline in Blurred Vision on the OSDI©

    The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Blurred Vision question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening.

    Time frame: Baseline, Month 6

  9. Change From Baseline in Poor Vision on the OSDI©

    The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Poor Vision question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening.

    Time frame: Baseline, Month 6

  10. Change From Baseline in Reading on the OSDI©

    The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Reading question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening.

    Time frame: Baseline, Month 6

  11. Change From Baseline in the Ocular Discomfort Scale Post Wilkins Test in the Worst Eye

    Participants assessed ocular discomfort post Wilkins Rate of Reading Test using the Ora Calibra™ 5-point scale where 0=no discomfort to 4=constant discomfort. A positive number change from Baseline indicates a worsening and a negative number change from Baseline indicates an improvement.

    Time frame: Baseline, Month 6

07

Results

Posted Jun 1, 2017

Participant flow

Participant flow — Overall Study
MilestoneRESTASIS®
Started51
Completed46
Not completed5
Withdrew: Adverse event1
Withdrew: Administrative reasons1
Withdrew: Other miscellaneous reasons3

Outcome measures

PrimaryChange From Baseline in the Total Corneal Staining Score With Fluorescein in the Worse Eye

Total corneal staining with fluorescein was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).

Time frame:
Baseline, Month 6
Reported as:
Mean · score on a scale
Change From Baseline in the Total Corneal Staining Score With Fluorescein in the Worse Eye
score on a scaleRESTASIS®
Baseline7.05 ± 1.011
Change from Baseline at Month 6-1.51 ± 1.466
PrimaryChange From Baseline in the Total Conjunctival Staining Score With Fluorescein in the Worse Eye

Total conjunctival staining with fluorescein was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The sum of the total includes 2 regions of the conjunctiva, resulting in a maximum possible score of 8 (severe staining score of 4 in both regions). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).

Time frame:
Baseline, Month 6
Reported as:
Mean · score on a scale
Change From Baseline in the Total Conjunctival Staining Score With Fluorescein in the Worse Eye
score on a scaleRESTASIS®
Baseline4.57 ± 1.237
Change from Baseline at Month 6-0.61 ± 1.238
PrimaryChange From Baseline in the Central Region Staining Score With Fluorescein in the Worse Eye

Staining with fluorescein in the central region of the eye was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).

Time frame:
Baseline, Month 6
Reported as:
Mean · score on a scale
Change From Baseline in the Central Region Staining Score With Fluorescein in the Worse Eye
score on a scaleRESTASIS®
Baseline2.29 ± 0.441
Change from Baseline at Month 6-0.75 ± 0.656
PrimaryChange From Baseline in the Total Corneal Staining Score With Lissamine Green in the Worse Eye

Total corneal staining with lissamine green was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).

Time frame:
Baseline, Month 6
Reported as:
Mean · score on a scale
Change From Baseline in the Total Corneal Staining Score With Lissamine Green in the Worse Eye
score on a scaleRESTASIS®
Baseline4.00 ± 1.378
Change from Baseline at Month 6-0.34 ± 1.418
PrimaryChange From Baseline in the Total Conjunctival Staining Score With Lissamine Green in the Worse Eye

Total conjunctival staining with lissamine green was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The sum of the total includes 2 regions of the conjunctiva, resulting in a maximum possible score of 8 (severe staining score of 4 in both regions). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).

Time frame:
Baseline, Month 6
Reported as:
Mean · score on a scale
Change From Baseline in the Total Conjunctival Staining Score With Lissamine Green in the Worse Eye
score on a scaleRESTASIS®
Baseline3.99 ± 1.486
Change from Baseline at Month 6-0.18 ± 1.235
PrimaryChange From Baseline in the Central Region Staining Score With Lissamine Green in the Worse Eye

Staining with lissamine green in the central region of the eye was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).

Time frame:
Baseline, Month 6
Reported as:
Mean · score on a scale
Change From Baseline in the Central Region Staining Score With Lissamine Green in the Worse Eye
score on a scaleRESTASIS®
Baseline0.85 ± 0.822
Change from Baseline at Month 6-0.24 ± 0.524
PrimaryChange From Baseline in Font Size

The minimum font (letter) size read correctly was assessed. Smaller font size (less points) indicates better ability. A negative change from Baseline indicates an improvement and a positive change from Baseline indicates a worsening.

Time frame:
Baseline, Month 6
Reported as:
Mean · points
Change From Baseline in Font Size
pointsRESTASIS®
Baseline9.0 ± 0.00
Change from Baseline at Month 60.0 ± 0.21
PrimaryChange From Baseline in Words Read Incorrectly

The numbers of words read incorrectly are counted. A positive change from Baseline indicates a worsening (more words read incorrectly) and a negative change from Baseline indicates an improvement.

Time frame:
Baseline, Month 6
Reported as:
Mean · incorrect words
Change From Baseline in Words Read Incorrectly
incorrect wordsRESTASIS®
Baseline16.6 ± 22.00
Change from Baseline at Month 6-4.1 ± 16.64
PrimaryChange From Baseline in Time to Read Passage

The time to read passage (selected portion of text ) in seconds was assessed. A negative change from Baseline indicates an improvement (less time to read the passage).

Time frame:
Baseline, Month 6
Reported as:
Mean · seconds
Change From Baseline in Time to Read Passage
secondsRESTASIS®
Baseline126.0 ± 28.64
Change from Baseline at Month 6-0.7 ± 24.48
PrimaryChange From Baseline in Reading Rate

Reading speed was assessed as the number of words read correctly calculated as words/minute. A positive change from Baseline indicates an improvement (more words read correctly/minute) and a negative change from Baseline indicates a worsening (less words read correctly/minute).

Time frame:
Baseline, Month 6
Reported as:
Mean · correct words/minute
Change From Baseline in Reading Rate
correct words/minuteRESTASIS®
Baseline146.6 ± 64.18
Change from Baseline at Month 6-3.6 ± 69.80
SecondaryChange From Baseline in Tear Film Break Up Time (TFBUT) in the Worse Eye

TFBUT is defined as the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. The worse eye is defined as the Worse Eye at Baseline. A positive number change from Baseline indicates improvement and a negative number change from Baseline indicates a worsening.

Time frame:
Baseline, Month 6
Reported as:
Mean · seconds
Change From Baseline in Tear Film Break Up Time (TFBUT) in the Worse Eye
secondsRESTASIS®
Baseline2.38 ± 1.073
Change from Baseline at Month 6-0.31 ± 1.258
SecondaryChange From Baseline in Ocular Protection Index (OPI) 2.0 in the Worse Eye

A device was used to assess OPI 2.0. This technology measures blink and tear film break-up area. These values demonstrate the average area of tear deficiency/corneal exposure. The worse eye is defined as the worse eye at Baseline. A negative value indicates an improvement in corneal protection.

Time frame:
Baseline, Month 6
Reported as:
Mean · percent of area
Change From Baseline in Ocular Protection Index (OPI) 2.0 in the Worse Eye
percent of areaRESTASIS®
Baseline1.38 ± 2.064
Change from Baseline at Month 6-0.87 ± 1.975
SecondaryChange From Baseline in Interblink Interval (IBI) in the Worst Eye

A device was used to assess IBI. The IBI measures the time in seconds between blinks in the worse eye. A positive number change from baseline indicates a worsening (more frequent blinks) and a negative number change from baseline (less frequent blinks) indicates an improvement.

Time frame:
Baseline, Month 6
Reported as:
Mean · seconds
Change From Baseline in Interblink Interval (IBI) in the Worst Eye
secondsRESTASIS®
Baseline5.27 ± 6.052
Change from Baseline at Month 6-1.16 ± 6.399
SecondaryChange From Baseline in OSDI© Total Score

The OSDI© questionnaire consists of 12 questions measuring the presence of ocular symptoms. Each of the 12 questions was assessed using a 5-point scale (where 0=none of the time and 4=all of the time). The score is converted to a 0 to 100 point score where 0 is no symptoms and 100 is most symptoms. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Month 6
Reported as:
Mean · score on a scale
Change From Baseline in OSDI© Total Score
score on a scaleRESTASIS®
Baseline45.1 ± 17.76
Change from Baseline at Month 6-14.9 ± 16.50
SecondaryChange From Baseline in Driving at Night on the OSDI©

The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Driving at Night question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening.

Time frame:
Baseline, Month 6
Reported as:
Mean · score on a scale
Change From Baseline in Driving at Night on the OSDI©
score on a scaleRESTASIS®
Baseline1.7 ± 1.30
Change from Baseline at Month 6-0.5 ± 1.14
SecondaryChange From Baseline in Working With a Computer or Bank Machine on the OSDI©

The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Working with a Computer or Bank Machine question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening.

Time frame:
Baseline, Month 6
Reported as:
Mean · score on a scale
Change From Baseline in Working With a Computer or Bank Machine on the OSDI©
score on a scaleRESTASIS®
Baseline1.9 ± 1.03
Change from Baseline at Month 6-0.8 ± 1.08
SecondaryChange From Baseline in Watching Television (TV) on the OSDI©

The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Watching TV question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening.

Time frame:
Baseline, Month 6
Reported as:
Mean · score on a scale
Change From Baseline in Watching Television (TV) on the OSDI©
score on a scaleRESTASIS®
Baseline1.8 ± 1.11
Change from Baseline at Month 6-0.9 ± 1.12
SecondaryChange From Baseline in Blurred Vision on the OSDI©

The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Blurred Vision question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening.

Time frame:
Baseline, Month 6
Reported as:
Mean · score on a scale
Change From Baseline in Blurred Vision on the OSDI©
score on a scaleRESTASIS®
Baseline1.7 ± 1.18
Change from Baseline at Month 6-0.6 ± 0.86
SecondaryChange From Baseline in Poor Vision on the OSDI©

The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Poor Vision question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening.

Time frame:
Baseline, Month 6
Reported as:
Mean · score on a scale
Change From Baseline in Poor Vision on the OSDI©
score on a scaleRESTASIS®
Baseline1.5 ± 1.23
Change from Baseline at Month 6-0.5 ± 0.84
SecondaryChange From Baseline in Reading on the OSDI©

The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Reading question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening.

Time frame:
Baseline, Month 6
Reported as:
Mean · score on a scale
Change From Baseline in Reading on the OSDI©
score on a scaleRESTASIS®
Baseline1.5 ± 1.25
Change from Baseline at Month 6-0.3 ± 1.15
SecondaryChange From Baseline in the Ocular Discomfort Scale Post Wilkins Test in the Worst Eye

Participants assessed ocular discomfort post Wilkins Rate of Reading Test using the Ora Calibra™ 5-point scale where 0=no discomfort to 4=constant discomfort. A positive number change from Baseline indicates a worsening and a negative number change from Baseline indicates an improvement.

Time frame:
Baseline, Month 6
Reported as:
Mean · score on a scale
Change From Baseline in the Ocular Discomfort Scale Post Wilkins Test in the Worst Eye
score on a scaleRESTASIS®
Baseline3.08 ± 1.017
Change from Baseline at Month 6-0.60 ± 1.232

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RESTASIS®—3/50 (6%)6/50 (12%)
Most frequent serious events
Most frequent serious events
EventRESTASIS®
Papillary thyroid carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/50
Peripheral vascular diseaseVascular disorders1/50
Carbon monoxide poisoningInjury, poisoning and procedural complications1/50
Most frequent other events
Most frequent other events
EventRESTASIS®
Visual acuity reducedEye disorders3/50
NasopharyngitisInfections and infestations3/50

Baseline characteristics

51 participants were initially enrolled in the study, 1 participant discontinued before dosing and is not included in the Intent-to-treat (ITT) population.

Age, Continuous
Age, Continuous(years)RESTASIS®
Mean46.3 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)RESTASIS®
Female41
Male9
08

Study locations

2 sites
  • Andover Eye Associates, Inc
    Andover, Massachusetts 01810, United States
  • Total Eye Care, PA
    Memphis, Tennessee 38119, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Mar 2016, 8 months.

Results were first posted in Jun 2017, 1 year 2 months after primary completion.

Of 28 industry-sponsored phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 15. This study's 8 months is close to that.

Counting every sponsor, half of 112 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2015
First posted
Sep 21, 2015
StartActual
Jul 21, 2015
Primary completionActual
Mar 24, 2016
CompletionActual
Mar 24, 2016
Results first posted
Jun 1, 2017
Last update
Jun 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02554981
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Sep 21, 2015
Start date
Jul 21, 2015
Primary completion
Mar 24, 2016
Completion
Mar 24, 2016
Results posted
Jun 1, 2017
Last update
Jun 1, 2017

Study contacts

Jai Parekh
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion